Collegium Pharmaceutical (NASDAQ:COLL) Downgraded to “Buy” at StockNews.com

StockNews.com cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a report issued on Wednesday.

COLL has been the subject of a number of other reports. HC Wainwright upped their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Truist Financial upped their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, Piper Sandler reiterated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $35.89 on Wednesday. Collegium Pharmaceutical has a 1-year low of $20.95 and a 1-year high of $42.29. The stock has a market cap of $1.17 billion, a PE ratio of 14.95 and a beta of 0.94. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. The firm has a fifty day moving average price of $37.69 and a 200 day moving average price of $35.39.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. During the same period in the prior year, the company earned $1.13 earnings per share. The business’s revenue was up 7.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Collegium Pharmaceutical will post 5.79 EPS for the current year.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several large investors have recently modified their holdings of COLL. Gladius Capital Management LP acquired a new stake in shares of Collegium Pharmaceutical in the second quarter valued at approximately $32,000. nVerses Capital LLC lifted its stake in shares of Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares during the period. GAMMA Investing LLC lifted its stake in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares during the period. CWM LLC lifted its stake in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the period. Finally, Sheaff Brock Investment Advisors LLC purchased a new position in shares of Collegium Pharmaceutical during the first quarter valued at approximately $204,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.